Interval Comparison of Zoledronic Acid Treatment in Patients with Metastatic Bone Disease, Is 4-Weekly or 12-Weekly More Effective?: A Systematic Review and Meta-analysis
Objectives: The aim of bisphosphonate treatment in patients with metastatic bone disease is to prevent metastatic skeletal morbidity and prevent cancer treatment-induced skeletal damage. The classical recommendation of Zoledronic acid treatment is to be given indefinitely as intravenous infusion every 3 to 4 weeks until patients' health deteriorates. Data on zoledronic acid's long-term effectiveness and safety are insufficient, and some recent literatures start to consider 12-weekly administration as a reasonable alternative in order to minimize the adverse effects.
Methods: A systematic search was conducted based on PRISMA guideline to identify relevant studies through PubMed, Google Scholar, and Cochrane database. A total of 5 studies (2867 patients) were included, divided into outcome analysis, processed using Review Manager 5.3.
Results: The search of electronic databases yielded a total of 299 entries. Five studies were included in the qualitative and quantitative synthesis following the steps of identifying, screening, determining eligibility, eliminating duplicates, and excluding studies. Out of a total of 2.867 patients, 1.427 received ZA for 12 weeks and 1.440 received ZA for 4 weeks, making up the total number of patients included in this meta-analysis. Each trial had a comparable one-year follow-up duration after ZA was given. We discovered that the incidence of adverse effects varied significantly between the two groups. In contrast, there is no statistically significant difference in the rates of SRE, ONJ, renal dysfunction, or death between the two groups.
Conclusion: Our systematic review and meta-analysis reveals that 12-week intervals of zoledronic acid is as effective as the standard 4-week interval in terms of skeletal related event, jaw osteonecrosis, renal dysfunction, and mortality rate. However, the standard 4-week intervals led to higher rate of adverse effects.
1. von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body J. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat Rev 2019;76:57–67.
2. D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options. J Bone Oncol 2019;15:100205.
3. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925–35.
4. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology Executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221–7.
5. Polascik T. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 2008;4:261–8.
6. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer 2004;100:44– 52.
7. Hutton B, Addison C, Mazzarello S, Joy AA, Bouganim N, Fergusson D, et al. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists. J Bone Oncol 2013;2:77–83.
8. Black DM, Reid IR, Boonen S, Bucci‐Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON‐Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243–54.
9. Kumar M, Dev P, Kainthla R. Compliance with every 12-week zoledronic acid dosing guidelines for bone metastasis in breast cancer patients. J Clin Oncol 2020;38:81.
10. Ibrahim MFK, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, et al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol 2015;26:2205–13.
11. Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial. JAMA Oncol 2017;3:906–12.
12. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013;14:663–70.
13. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial. JAMA 2017;317:48–58.